WuXi Advanced Therapies Sells Facilities; Sai Life Sciences, Univercells Expand

The latest from CDMOs, CMOs, and suppliers featuring WuXi Advanced Therapies, Sai Life Sciences, Univercells Technologies, Rondo-Pak, and Tjopack.

Chemicals/Chemical API Manufacturing

Sai Life Sciences Adds Cellular Analysis Suite
Sai Life Sciences, a Hyderabad, India-headquartered CDMO of intermediates and active pharmaceutical ingredients and discovery chemistry services, has expanded with the addition of cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts.

The expanded suite of services include the Opera Phenix high content screening platform, FACSCelesta flow cytometer, and FACSMelody flow sorter to enable biology research in oncology, neuroscience, and rare diseases.

Over the past year, the company says the lab has delivered a range of projects including genetic and pharmacological target validation studies, reagent validation, and developed a variety of assays for its clients, such as cellular target engagement assays and in vitro biomarker assessments.

Source: Sai Life Sciences

Biologics Manufacturing

WuXi Advanced Therapies Sells Facilities to Real Estate Firm
Ensemble Real Estate Investments, a Long Beach, California-based company, has closed on the purchase of three large life-sciences facilities in Philadelphia occupied by WuXi Advanced Therapies, part of WuXi AppTec and a CDMO for advanced therapies.

The properties in Philadelphia’s Navy Yard comprise a collective 366,803 square feet. The closing on the WuXi facilities expands Ensemble’s Navy Yard Life Sciences footprint to a total of five properties that represent approximately 550,000 square feet and $155 million invested.

The real-estate’s firms other life-sciences properties are the US headquarters of Adaptimmune Therapeutics, an Oxfordshire, UK-based T-cell therapy company, and the currently under-construction facility of Iovance Biotherapeutics, a late-stage biopharmaceutical company specializing in immunotherapies for cancer, where they are the co-developer.

Source: Ensemble Real Estate Investments

Univercells Introduces Upstream Bioprocessing Platform
Univercells Technologies, a technology company specializing in bioprocessing, is introducing NevoLine Upstream platform as part of its Nevoline biomanufacturing platform.

The upstream manufacturing platform is suitable for multiple viral applications for gene therapies and vaccines. It intensifies and chains all unit operations from inoculation to mid-stream processing to deliver a concentrated, clarified bulk product. The platform enables commercial-scale upstream production in a 3-m² module. The automated platform offers a service suited for multiple viral applications by combining single-use assemblies in process-specific configurations.

Commercial launch is planned for November (November 2020).

Source: Univercells Technologies


Rondo-Pak Names New President
Rondo-Pak LLC, a joint venture with Körber Pharma group (formerly Körber Medipak Systems), has named Bob Reilley as its President and Chief Operating Officer (COO).

Mr. Reilley had been in the COO role for four years. Now as President and COO, he will continue to oversee North American operations, including facilities in New Jersey and Puerto Rico and will take a lead role in strategic planning, client acquisition and retention and be the connection between Rondo-Pak and the Körber Pharma Group. He has been in a leadership role within the company for 10 years.

Prior to joining Rondo-Pak, Mr. Reilley served as a Global Director for Catalent Pharma Solutions’ Printed Components Division.

Source: Rondo-Pak

Tjopack To Expand Vial and Prefilled Syringe Capacity
Tjoapack, a North Brabant, Netherlands-based contract packaging organization, is investing to expand its operations in automated packaging for pre-filled syringes and vials.

The company says the new fully automated packaging line for vials will start operations in the first quarter of 2021 and will increase its capacity to over 12 million vials per year. Pre-filled syringes (PFS) capabilities are expected to be fully operational by the fourth quarter of 2021. The fully automated PFS packaging line will have an initial capacity for 7 million syringes per year and will be able to assemble, automate insertion of plunger rods and back-stops, carry out inline labelling, and complete coding and vision control.

Source: Tjoapack

Leave a Reply

Your email address will not be published. Required fields are marked *